Compare Nuscale Power Corporation (SMR) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuscale Power Corporation vs Stryker Corporation — how do they compare? Nuscale Power Corporation trades at $7.2 (market cap $3.00B), while Stryker Corporation trades at $277.34 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 35.4× Nuscale Power Corporation's market cap, and Stryker Corporation pays a 1.27% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuscale Power Corporation for 29 Days and Stryker Corporation for 21 Days on average.
| SMR | SYK | |
|---|---|---|
Market Cap | $3.00B | $106.24B |
Volume | 43,143,109 | 2,982,001 |
Sector | Industrials | Health |
52-Week High | $53.43 | $388.35 |
52-Week Low | $7.32 | $269.75 |
Typical Hold Time | 29 Days | 21 Days |
Enterprise Value | $1.93B | $117.70B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NuScale Power (SMR) trades at $7.20, down 6.13% with bearish technical signals. The company shows concerning fundamentals with negative net income margins (-3,888.7% in 2026) despite analyst consensus of $11.25 price target. Recent news highlights ongoing investor investigations and competitive pressures in the nuclear energy sector.
While analysts maintain 50% buy ratings, significant operational losses and cash burn create substantial risk. The stock faces headwinds from execution challenges and dilution concerns, though long-term nuclear energy adoption trends provide potential upside for patient investors.
Stryker (SYK) trades at $277.33, up 0.7% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus. Recent news highlights ongoing legal scrutiny related to a manufacturing issue disclosed in September 2026, which caused an 8.8% stock drop, but the company continues to innovate with product launches like Prophecy surgical planning.
The outlook for SYK is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities include robust profitability and growth in medical technology, but risks persist from legal investigations and potential operational disruptions. Investors should weigh strong analyst support against near-term sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
